Novel combo therapy using oncolytic adenovirus and immune drugs for pancreatic cancer
Official title: Novel combination immunotherapy with oncolytic adenovirus and immune checkpoint inhibitors for pancreatic ductal adenocarcinoma.
Funded at Uinta Bio, INC. · NIH-11407396 · Data updated 2026-11-12
Aims to combine an oncolytic virus with immune therapies to help shrink pancreatic tumors before surgery and keep them from coming back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Uinta Bio, INC. NIH-funded |
| Lab location | 1 site (Park City, UNITED STATES) |
| Project start | September 14, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $306,388 |
| NIH project number | 1R41CA314730-01 |
| Project ID | NIH-11407396 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with resectable pancreatic ductal adenocarcinoma who are candidates for neoadjuvant therapy.
✕Less likely to help
Patients with advanced or unresectable disease or those unable to tolerate immunotherapy or virotherapy may not benefit.
What this research studies
This grant explores a new treatment plan for pancreatic cancer by giving an engineered virus alongside immune therapies before surgery to make tumors easier to remove and reduce relapse. The approach focuses on overcoming the tumor’s defenses that usually make immunotherapy less effective. By breaking down the tumor barriers and revving up immune cells, the therapy hopes to improve treatment outcomes for patients with resectable PDAC. The research will look at how well this combination works and how it changes the tumor environment in early stages of disease.
Why it matters
Potential benefit: If successful, patients with pancreatic cancer could have higher chances of successful tumor removal and longer disease-free periods.
How similar studies have gone: Preliminary evidence suggests combining oncolytic viruses with immunotherapy can modify the tumor environment and enhance responses in some cancers, but this exact combination in PDAC is investigational.
Where this research is happening
-
Uinta Bio, INC.
Park City, United States Active
Researchers
- Principal investigator: Stock, Charlotte Anne Casebourne — Uinta Bio, INC.
- Study coordinator: Stock, Charlotte Anne Casebourne
Related research
Other NIH-funded projects on the same topics.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Combining a targeted tumor‑ablation technique with immunotherapy for pancreatic cancer
Seeing if pairing irreversible electroporation (a focused tumor‑destroying procedure) with immune‑boosting drugs can help people with pancreatic ductal adenocarcinoma respond better to treatment.
-
Understanding how immunotherapy works in pancreatic cancer
This study is looking at why some people with pancreatic cancer benefit from immunotherapy while others don’t, and it aims to find better treatment combinations that can help boost the immune system's fight against this tough cancer.
-
Using electrical pulses to enhance cancer immunotherapy for pancreatic cancer
This study is looking at how using electrical pulses to destroy pancreatic cancer cells, along with immune therapy, might help make the cancer more responsive to treatment and improve survival for patients with pancreatic ductal adenocarcinoma.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.